Cassava Sciences Inc
Затворен
СекторЗдравеопазване
2.1
Преглед
Промяна на цената на акция
24 ч
Минимум
2.1
Максимум
2.1
Приходи | -1.7M -13M |
|---|---|
Продажби | 840K 840K |
Марж на печалбата | -1,492.738 |
Служители | 30 |
EBITDA | -39M -50M |
Пазарна капитализация | -4.3M 142M |
|---|---|
Предишно отваряне | 2.1 |
Предишно затваряне | 2.1 |
Техническа оценка
By Trading Central
Увереност
Weak Bearish Evidence
Cassava Sciences Inc Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Cassava Sciences Inc Прогноза
Финанси
$
Относно Cassava Sciences Inc
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.